



IMMUNOVIA TO PRESENT AT AKTIESPARARNA'S LIFE SCIENCE EVENT ON APRIL 23

Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, will participate in Aktiespararna's digital Life Science theme night on April 23, 2025. Hosted by the Swedish Shareholders' Association (Aktiespararna), the event brings together individual investors and a selection of listed Life Science companies for an evening of company presentations, market analysis, and investment insights.

During the event, Immunovia's CEO Jeff Borcharding will outline the company's near-term priorities and next steps, focusing on the ongoing commercialization efforts and clinical study milestones that are critical to enabling reimbursement and broader market adoption.

Immunovia's presentation is scheduled to begin at 18:45 CET and will be held in English. The live-streamed event is open to all members of Aktiespararna.

For further information, please contact

Jeff Borcharding, CEO
jeff.borcharding@immunovia.com

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.